Skip to content
Pomalyst, Imnovid (previously pomalidomide celgene)(pomalidomide)
Imnovid, Pomalyst (pomalidomide) is a small molecule pharmaceutical. Pomalidomide was first approved as Pomalyst on 2013-02-08. It is used to treat kaposi sarcoma and multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon.
Download report
Favorite
SARS-CoV-2 Interaction
BMS
Case Study: Multiple Myeloma
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Pomalyst (generic drugs available since 2022-01-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pomalidomide
Tradename
Company
Number
Date
Products
POMALYSTBristol Myers SquibbN-204026 RX2013-02-08
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
pomalystNew Drug Application2020-12-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
kaposi sarcoma—D012514C46
multiple myeloma—D009101C90.0
Agency Specific
FDA
EMA
Expiration
Code
POMALIDOMIDE, POMALYST, BRISTOL
2027-11-14PED
2027-05-14ODE-296, ODE-297
2024-05-20PED
2023-11-20M-14
Patent Expiration
Patent
Expires
Flag
FDA Information
Pomalidomide, Pomalyst, Bristol
88284272031-06-21DS, DP
99934672030-05-19DP
105559392030-05-19DP
81982622025-06-17U-1360, U-2254
86739392023-05-15U-1360, U-2254
87354282023-05-15U-1360, U-2254
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AX: Other immunosuppressants in atc
— L04AX06: Pomalidomide
HCPCS
No data
Clinical
Clinical Trials
230 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.069972638169
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728D47.4121——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Immunoglobulin light-chain amyloidosisD00007536335———6
Kaposi sarcomaD012514C4633———5
NeoplasmsD009369C8033———4
Non-hodgkin lymphomaD008228C85.942———4
Plasma cell neoplasmsD05421913———3
Large b-cell lymphoma diffuseD016403C83.321———3
Myeloid leukemia acuteD015470C92.022———3
RecurrenceD012008—2———2
Myelomonocytic leukemia chronicD015477C93.111———2
Hereditary hemorrhagic telangiectasiaD013683I78.011———2
Show 28 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Waldenstrom macroglobulinemiaD008258C88.03————3
Healthy volunteers/patients—3————3
Intraocular lymphomaD0640901————1
Therapeutic equivalencyD0138101————1
Neurofibromatosis 1D009456Q85.011————1
Sickle cell anemiaD000755EFO_0000697D571————1
Burkitt lymphomaD002051C83.71————1
Plasmablastic lymphomaD000069293C83.31————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePOMALIDOMIDE
INNpomalidomide
Description
Pomalidomide is an aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies. It has a role as an antineoplastic agent, an immunomodulator and an angiogenesis inhibitor. It is a dicarboximide, a member of isoindoles, a member of piperidones and an aromatic amine. It is functionally related to a thalidomide.
Classification
Small molecule
Drug classthalidomide derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O
Identifiers
PDB—
CAS-ID19171-19-8
RxCUI1369713
ChEMBL IDCHEMBL43452
ChEBI ID72690
PubChem CID134780
DrugBankDB08910
UNII IDD2UX06XLB5 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CRBN
CRBN
Organism
Homo sapiens
Gene name
CRBN
Gene synonyms
NCBI Gene ID
51185
Protein name
protein cereblon
Protein synonyms
protein x 0001
Uniprot ID
Q96SW2
Mouse ortholog
Crbn (58799)
protein cereblon (Q8C7D2)
Variants
Clinical Variant
No data
Financial
Pomalyst - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Pomalyst - Celgene
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,977 documents
View more details
Safety
Black-box Warning
Black-box warning for: Pomalyst
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,167 adverse events reported
View more details